Acme United Corporation enters the final trading day of April nursing its worst weekly loss in recent memory — down 9.4% on the week to $41.66, with a further 0.8% decline on Tuesday. The most striking part of the setup isn't the short interest rebuild. It's that the CEO, CFO, and COO sold a combined $2.75 million worth of stock at $45.88 on February 27, and the stock has since fallen through that exit price.
The insider sales are the standout detail of this week. On February 27, three members of the senior leadership team — Chairman and CEO Walter Johnsen, CFO Paul Driscoll, and President and COO Brian Olschan — each filed sales at $45.88, together offloading 60,000 shares for just under $2.75 million net. The current price of $41.66 is roughly 9% below that sale price. Those transactions followed a pattern of smaller disposals by the COO through May and June 2025, all in the $39–$40 range. The company's largest named holder, Walter Johnsen himself, still held 314,999 shares as of March 10 — so this was a trim rather than an exit — but the coordinated nature of the February sales, at what now looks like a local high, is notable context as the stock softens.
Short positioning has quietly picked up alongside the price decline, though it remains modest rather than aggressive. Short interest came to 3.05% of the free float as of April 28, up 19% on the week and back near mid-April levels after briefly dipping toward 2.6% on April 23. The week's most telling number is that one-week jump: roughly 15,000 additional shares short added during a 9% selloff suggests incremental positioning rather than a heavy short thesis. Borrow conditions remain loose — cost to borrow has actually eased over the past month, halving from peaks above 3% in late March to just 0.81% now, and availability is not remotely strained. The ORTEX short score of 41.9 — in the middle of its range for the past fortnight — reflects a story of modest and gradually rising short interest, not crowded positioning.
The price move itself is the dominant fact this week. ACU closed at $41.66 after touching intraday lows closer to $41. It has lost 5% over the past month and is now trading below every insider's February sell price. Among its correlated peers, DRTS fared even worse, dropping 7.7% on the day alone. GEHC shed 5.2% on the week and EMBC gave up about 1.1%, suggesting broader weakness across health-care supply names rather than an ACU-specific dislocation.
Analyst data is dated — the most recent target on record, from Freedom Broker in May 2025, pegged fair value at $50 after a cut from $58. That figure is now more than a year old and carries limited weight given the stock's subsequent price action. With no near-term earnings event flagged, the watch points are whether short interest continues to climb through the current ~3% level as the price softens, and whether any of the senior executives who sold in February initiate new purchases — which, at current prices, would represent a material change in the insider signal.
See the live data behind this article on ORTEX.
Open ACU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
